Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

31.28 -1.32 (-4.05%)

Delayed Quote Updated: 11:55 AM EDT, Oct 1, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Viking Therapeutics, Inc. - Common Stock

< Previous 1 2

...

20 21 22 23 24 25 26 27 28

...

34 35 Next >

Missed Out on Novo Nordisk? 2 Healthcare Stocks With Big Catalysts on the Horizon. ↗

April 24, 2024

Good news could be just around the corner for two drugmakers not named Novo Nordisk.

Via The Motley Fool

Better Buy: Pfizer vs. Viking Therapeutics ↗

April 23, 2024

These two pharma stocks have followed distinct paths of late. Which is the better investment?

Via The Motley Fool

1 No-Brainer Vanguard Fund to Buy Right Now ↗

April 23, 2024

This Vanguard growth fund is home to some of the world's most innovative companies.

Via The Motley Fool

3 Stocks With the Potential to Surpass Analyst Expectations for 2024 ↗

April 23, 2024

These stocks to buy are set to surpass analyst expectations, with exciting product and service developments sparking unforeseen growth.

Via InvestorPlace

Looking At Viking Therapeutics's Recent Unusual Options Activity ↗

April 22, 2024

Via Benzinga

Market Whales and Their Recent Bets on VKTX Options ↗

April 18, 2024

Via Benzinga

$100 Invested In Viking Therapeutics 5 Years Ago Would Be Worth This Much Today ↗

April 15, 2024

Via Benzinga

Viking Therapeutics's Options: A Look at What the Big Money is Thinking ↗

April 09, 2024

Via Benzinga

Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?

April 22, 2024

The GLP-1 weight loss trend continues to flourish, and the ante keeps rising; see how the winner between Wegovy and Zepbound can help your portfolio

Via MarketBeat

These 3 Biotech Stocks Are Up 269% in 2024. Is There More to Come? ↗

April 16, 2024

These three biotech stocks are leading the sector higher on upbeat news but is this as good as it gets or do they have more gas in the tank?

Via InvestorPlace

Viking Therapeutics: Strong Results In Obesity ↗

April 13, 2024

With a potential best in class drug for oral and injectable use, Viking Therapeutics has to be on many Big Pharma/Bio acquisition wish lists, as the company represents a very scarce asset in the $100...

Via Talk Markets

3 Magnificent Stocks That Could Double or More by 2030 ↗

April 13, 2024

There's no guarantee these stocks will double by 2030, but their growth prospects look great.

Via The Motley Fool

Shed the Fat, Gain the Profits: 3 Weight-Loss Stocks to Own Until 2027 ↗

April 12, 2024

For investors looking for a way to play weight-loss stocks in this current backdrop, here are three top options to consider right now.

Via InvestorPlace

Is it Too Late to Buy Viking Therapeutics Stock? ↗

April 06, 2024

Viking Therapeutics stock is on fire following a successful phase 2 trial for its obesity care candidate.

Via The Motley Fool

Viking Therapeutics Just Announced More Positive Results: Time to Buy? ↗

April 04, 2024

The drugmaker isn't losing momentum.

Via The Motley Fool

If You Can Only Buy One Biotech Stock in April, It Better Be One of These 3 Names ↗

April 11, 2024

Capitalize on the biotech sector's boom with these three top biotech stocks to buy, driven by aging demographics and advanced treatments.

Via InvestorPlace

Better Buy: CRISPR Therapeutics Vs. Viking Therapeutics ↗

April 09, 2024

These rising drugmakers have serious arguments in their favor.

Via The Motley Fool

Forget Viking Therapeutics. Here's 1 Weight-Loss Stock to Keep Your Eyes on Instead. ↗

April 09, 2024

Viking Therapeutics has garnered a lot of attention following a successful clinical trial for its obesity care drug. But another development-stage biotech may have a superior candidate.

Via The Motley Fool

Can Altimmune get its GLP-1 Drug to Market Before Cash Rush Out?

April 09, 2024

Altimmune has a GLP-1 candidate in Phase 2 trials, but the company continues to burn cash and may need a big pharma partner to get its drug to market

Via MarketBeat

Viking Therapeutics Is Great. Here's Why You Shouldn't Buy It. ↗

April 08, 2024

Shares of the clinical-stage biotech have skyrocketed on recent good news.

Via The Motley Fool

MarketBeat Week in Review – 4/1 - 4/5

April 06, 2024

Equities lost ground this week as investors consider the effect of fewer rate cuts, rising oil prices, and robust job gains ahead of a new earnings season

Via MarketBeat

Topics Economy

Better Booming Biotech Stock: Madrigal Pharmaceuticals vs. Viking Therapeutics ↗

April 05, 2024

These businesses should see good times ahead.

Via The Motley Fool

10 Health Care Stocks Whale Activity In Today's Session ↗

April 04, 2024

Via Benzinga

1 Brand-New (Good) Reason to Buy Viking Therapeutics Stock Now ↗

April 04, 2024

Its long-term growth potential looks like it's improving, again.

Via The Motley Fool

2 Potentially Explosive Stocks to Buy in April ↗

April 04, 2024

These two healthcare stocks should have plenty of room to run.

Via The Motley Fool

Could This 1 Detail Help Viking Therapeutics Top Eli Lilly and Novo Nordisk in the Weight Loss Drug Market? ↗

April 04, 2024

Viking shares have soared recently on optimism about its program.

Via The Motley Fool

10 Health Care Stocks Whale Activity In Today's Session ↗

April 03, 2024

Via Benzinga

Viking Therapeutics Surges Sentiment for Triple Threat GLP-1Pill

April 03, 2024

Viking Therapeutics is preparing to be the next entry into the GLP-1 Market, and VKTX stock is soaring as analysts start to bid the stock higher

Via MarketBeat

5 Healthcare Stocks to Buy for 2024 ↗

April 02, 2024

Healthcare stocks have been some of the top performers in 2024, and thanks to the potential of AI, these names will just keep heating up.

Via InvestorPlace

Topics Artificial Intelligence

Merger Mania: 3 Potential Takeover Targets to Watch for Lucrative Buyouts ↗

April 02, 2024

With interest rates poised to fall, acquisitions will become more numerous. Here are three potential takeover targets.

Via InvestorPlace

< Previous 1 2

...

20 21 22 23 24 25 26 27 28

...

34 35 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.